Cargando…

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

BACKGROUND: Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid. The objective of our study was to prospectively estimate the association between gliptins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambadiari, Vaia, Kountouri, Aikaterini, Kousathana, Foteini, Korakas, Emmanouil, Kokkalis, Georgios, Theotokoglou, Sofia, Palaiodimou, Lina, Katsimbri, Pelagia, Ikonomidis, Ignatios, Theodoropoulos, Konstantinos, Papadavid, Evangelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879621/ https://www.ncbi.nlm.nih.gov/pubmed/33573656 http://dx.doi.org/10.1186/s12902-021-00689-7

Ejemplares similares

The Effect of Antioxidant and Anti-Inflammatory Capacity of Diet on Psoriasis and Psoriatic Arthritis Phenotype: Nutrition as Therapeutic Tool?
por: Katsimbri, Pelagia, et al.
Publicado: (2021)

Additive prognostic value of longitudinal myocardial deformation to SCORE2 in psoriasis
por: Makavos, George, et al.
Publicado: (2023)

Echocardiography, an Indispensable Tool for the Management of Diabetics, with or without Coronary Artery Disease, in Clinical Practice
por: Katogiannis, Konstantinos, et al.
Publicado: (2020)

Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis
por: Ikonomidis, Ignatios, et al.
Publicado: (2022)

Familial Partial Lipodystrophy: Clinical Features, Genetics and Treatment in a Greek Referral Center
por: Kountouri, Aikaterini, et al.
Publicado: (2023)

Type 1 Diabetes Mellitus in the SARS-CoV-2 Pandemic: Oxidative Stress as a Major Pathophysiological Mechanism Linked to Adverse Clinical Outcomes
por: Kountouri, Aikaterini, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Endothelial Dysfunction Is Associated with Decreased Nitric Oxide Bioavailability in Dysglycaemic Subjects and First-Degree Relatives of Type 2 Diabetic Patients
por: Ikonomidis, Ignatios, et al.
Publicado: (2022)

COVID-19, Endothelium and the Cardiometabolic Patient: A Possible Role for Capillary Leak Syndrome
por: Lambadiari, Vaia, et al.
Publicado: (2022)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Effects of Treatment With Continuous Subcutaneous Insulin Infusion on Arterial Stiffness and Endothelial Glycocalyx Compared to MDI Intensification in Patients With Type 1 Diabetes: Improvement After a Six-Month Pump Treatment
por: Kountouri, Aikaterini, et al.
Publicado: (2021)

Pre-Existing Cytokine and NLRP3 Inflammasome Activation and Increased Vascular Permeability in Diabetes: A Possible Fatal Link With Worst COVID-19 Infection Outcomes?
por: Lambadiari, Vaia, et al.
Publicado: (2020)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid()()
por: Gravani, Agoritsa, et al.
Publicado: (2021)

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor – A case report
por: Karthik, S, et al.
Publicado: (2019)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors: A report of five cases
por: Yoshiji, Satoshi, et al.
Publicado: (2017)

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
por: Pasmatzi, Efi, et al.
Publicado: (2011)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
por: Kinyó, Ágnes, et al.
Publicado: (2021)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
por: Ikonomidis, Ignatios, et al.
Publicado: (2020)

Bariatric Surgery and Type 1 Diabetes: Unanswered Questions
por: Korakas, Emmanouil, et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
por: Hung, Chih-Tsung, et al.
Publicado: (2022)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
por: Balighi, Kamran, et al.
Publicado: (2022)

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
por: Nozawa, Keisuke, et al.
Publicado: (2023)

Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow–Up Study
por: Lambadiari, Vaia, et al.
Publicado: (2019)

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
por: Lambadiari, Vaia, et al.
Publicado: (2021)

Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19
por: Ikonomidis, Ignatios, et al.
Publicado: (2020)

Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
por: Kawaguchi, Yohei, et al.
Publicado: (2018)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
por: Shinohara, Yasutake, et al.
Publicado: (2020)

Prevalence and Prognostic Factors of Stress Hyperglycemia in a Pediatric Population with Acute Illness in Greece—A Prospective Observational Study
por: Korakas, Emmanouil, et al.
Publicado: (2022)

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
por: Mai, Yosuke, et al.
Publicado: (2019)

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
por: Bukvić Mokos, Zrinka, et al.
Publicado: (2020)

Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul
por: Ugurer, Ece, et al.
Publicado: (2022)

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Iwamoto, Yuichiro, et al.
Publicado: (2022)

Association of Hypoglycemia with Biomarkers of Oxidative Stress and Antioxidants: An Observational Study
por: Papachristoforou, Eleftheria, et al.
Publicado: (2022)

Stress Hyperglycemia in Children and Adolescents as a Prognostic Indicator for the Development of Type 1 Diabetes Mellitus
por: Argyropoulos, Theodoros, et al.
Publicado: (2021)

The Effects of Different Hormones on Supraventricular and Ventricular Premature Contractions in Healthy Premenopausal Women
por: Tsougos, Elias, et al.
Publicado: (2021)

Diabetes and COVID-19; A Bidirectional Interplay
por: Kazakou, Paraskevi, et al.
Publicado: (2022)

SARS‐CoV‐2 vaccine‐triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors‐associated bullous pemphigoid
por: Nakahara, Yukiko, et al.
Publicado: (2022)

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
por: Mai, Yosuke, et al.
Publicado: (2018)

Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
por: Harada, Masaru, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6pj619mh9rh90tf888pr3pnehj